

# Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure

Rocco Barazzoni<sup>1,2\*</sup>, Gianluca Gortan Cappellari<sup>1,2</sup>, Sandra Palus<sup>3</sup>, Pierandrea Vinci<sup>1,2</sup>, Giulia Ruozi<sup>4</sup>, Michela Zanetti<sup>1,2</sup>, Annamaria Semolic<sup>1,2</sup>, Nicole Ebner<sup>3</sup>, Stephan von Heahling<sup>3</sup>, Gianfranco Sinagra<sup>5,2</sup>, Mauro Giacca<sup>4</sup> & Jochen Springer<sup>3</sup>

<sup>1</sup>Internal Medicine, Department of Medical, Surgical and Health Sciences—University of Trieste, Trieste, Italy; <sup>2</sup>Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS), Trieste, Italy; <sup>3</sup>Department of Cardiology & Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany; <sup>4</sup>Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy; <sup>5</sup>Cardiology Division, Department of Medical, Surgical and Health Sciences—University of Trieste, Trieste, Italy

## Abstract

**Background** Chronic heart failure (CHF) is associated with skeletal muscle abnormalities contributing to exercise intolerance, muscle loss, and negative impact on patient prognosis. A primary role has been proposed for mitochondrial dysfunction, which may be induced by systemic and tissue inflammation and further contribute to low insulin signalling. The acylated form of the gastric hormone ghrelin (AG) may improve mitochondrial oxidative capacity and insulin signalling in both healthy and diseased rodent models.

**Methods** We investigated the impact of AG continuous subcutaneous administration (AG) by osmotic minipump (50 nmol/kg/day for 28 days) compared with placebo (P) on skeletal muscle mitochondrial enzyme activities, mitochondrial biogenesis regulators transcriptional expression and insulin signalling in a rodent post-myocardial infarction CHF model.

**Results** No statistically significant differences (NS) were observed among the three groups in cumulative food intake. Compared with sham-operated, P had low mitochondrial enzyme activities, mitochondrial biogenesis regulators transcripts, and insulin signalling activation at AKT level ( $P < 0.05$ ), associated with activating nuclear translocation of pro-inflammatory transcription factor nuclear factor- $\kappa$ B. AG completely normalized all alterations ( $P < 0.05$  vs P,  $P = \text{NS}$  vs sham-operated). Direct AG activities were strongly supported by *in vitro* C2C12 myotubes experiments showing AG-dependent stimulation of mitochondrial enzyme activities. No changes in mitochondrial parameters and insulin signalling were observed in the liver in any group.

**Conclusions** Sustained peripheral AG treatment with preserved food intake normalizes a CHF-induced tissue-specific cluster of skeletal muscle mitochondrial dysfunction, pro-inflammatory changes, and reduced insulin signalling. AG is therefore a potential treatment for CHF-associated muscle catabolic alterations, with potential positive impact on patient outcome.

**Keywords** Ghrelin; Skeletal muscle; Mitochondria; Insulin signalling

Received: 28 September 2017; Accepted: 2 October 2017

\*Correspondence to: Rocco Barazzoni, Dept. of Medical, Surgical and Health Sciences, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy. Phone: 39-0403994416, Email: barazzoni@units.it

## Introduction

Incidence and prevalence of chronic heart failure (CHF) are increasing worldwide, and CHF-associated morbidity and mortality are a major health problem.<sup>1,2</sup> CHF commonly

causes skeletal muscle (SM) metabolic and functional alterations that lead to exercise intolerance and ultimately muscle loss with strong negative impact on patient outcome.<sup>3–10</sup> Altered energy metabolism with low mitochondrial oxidative capacity has been proposed to play a primary role in CHF-

induced SM changes.<sup>3,11,12</sup> Cardiac and systemic pro-inflammatory signalling activation has been conversely hypothesized to contribute to low tissue mitochondrial function,<sup>13,14</sup> and skeletal muscle inflammation and mitochondrial dysfunction could further impair insulin signalling<sup>15–18</sup> thereby collectively enhancing muscle catabolism. Effective therapeutic strategies to counteract CHF-induced SM mitochondrial dysfunction and its potential metabolic consequences are therefore urgently needed.

The gastric hormone acylated ghrelin (AG) has orexigenic effects and complex metabolic activities that may include stimulation of SM mitochondrial oxidative capacity and insulin signalling in both healthy and diseased rodent models.<sup>19–22</sup> Despite potential negative effects on circulating glucose reported in human and experimental models due to potential glucogenic activities,<sup>19,20,23</sup> AG has been therefore extensively studied and increasingly suggested as potential anti-catabolic treatment under chronic disease conditions associated with loss of body and muscle mass.<sup>8,22,24–26</sup> We and others have shown beneficial effects of AG on body weight, muscle mass, and systemic inflammation in cancer and renal cachexia models.<sup>21,27,28</sup> In experimental chronic kidney disease, we specifically demonstrated that sustained peripheral AG administration enhances skeletal muscle mitochondrial function also independently of food intake.<sup>21</sup> No information is, however, available on potential effects of AG administration on skeletal muscle mitochondrial function and insulin signalling in CHF. In addition, no studies investigated potential AG effects on skeletal muscle inflammation as potential mediator of AG metabolic activities in cachexia-inducing diseases *in vivo*.

In the current study, we therefore investigated the impact of continuous 28 day AG subcutaneous administration on SM mitochondrial enzyme activities, transcriptional expression of mitochondrial biogenesis regulators as well as insulin signalling and pro-inflammatory pathways in a rodent post-myocardial infarction (IMA) CHF model. Direct AG effects on mitochondrial function and enzyme activities were further verified *in vitro* in C2C12 myotubes, whereas animals were studied *in vivo* at AG doses reported to prevent global alterations in food intake through the whole experimental period.<sup>29</sup> Because AG was previously reported to reduce systemic inflammation markers in different chronic disease models<sup>27</sup> and systemic inflammation may be activated in CHF with potential negative impact on SM inflammatory pathways and mitochondrial and metabolic dysfunction,<sup>13,14</sup> we further examined whether activating nuclear translocation of the master pro-inflammatory transcription factor nuclear factor- $\kappa$ B (NF $\kappa$ B) is altered in CHF and normalized by AG. The same parameters were finally investigated in the liver to determine potential tissue distribution and specificity of AG activities because differential acylated ghrelin effects were reported at hepatic level with potential to negatively affect plasma metabolic profile.<sup>19,20,23</sup>

## Materials and methods

### Experimental protocol and measurements

#### Animal surgery and treatments

All procedures were approved by the competent ethics committee (Ladesamt für Gesundheit und Soziales Berlin, Germany; permit number G 0116/05). The study was designed to determine the effects of ghrelin or ghrelin analogues on body weight and composition in chronic heart failure, and part of the study results have been published elsewhere.<sup>29,30</sup> 215–230 g male Sprague Dawley rats (Harlan-Winkelmann, Borchon, Germany) underwent surgical procedures with thoracotomy and either coronary artery ligation (IMA) or sham operation with thoracotomy and cardiac exposure without ligation of the coronary artery (Control).<sup>29,30</sup> All rats were treated with buprenorphine for 2 days following surgery for analgesia; 24 h mortality was 31%. Surviving animals were caged individually and fed standard chow under a 12 h light cycle; all rats were treated with furosemide starting 14 days after surgery.<sup>29,30</sup> After two additional weeks, IMA animals were further randomized ( $n = 18$  each) to receive either placebo (IMA-P) or human ghrelin at 50 nmol/kg/day (IPSEN Pharmaceuticals; IMA-AG) via osmotic minipumps implanted subcutaneously on the back (Charles River, Sulzfeld, Germany); control animals received placebo via the same route ( $n = 14$ ). After 14 day infusions, minipumps were replaced on Day 42 from surgery; animals were then sacrificed at Day 56 from surgery after identical additional 14 day infusions. Animal body weight and food intake were recorded twice weekly throughout the study period; body weight changes were analysed and compared among groups during the first week of each infusion period, that is, at Days 28–36 and 42–50 after initial surgery. Echocardiography was performed prior to sacrifice, using a 15 MHz probe and an Acuson Sequoia system (Siemens, Erlangen, Germany); animals with infarct size less than 25% of left ventricle were excluded from analyses ( $n = 5$ ).

#### Cytochrome c oxidase and citrate synthase activities and RNA analysis

Mitochondrial cytochrome c oxidase and citrate synthase enzyme activities were measured spectrophotometrically from muscle homogenates as referenced.<sup>31</sup> Total RNA was isolated from 40–50 mg of gastrocnemius muscle (Tri Reagent, MRC, Cincinnati, OH, USA). Transcript levels of regulators of mitochondrial biogenesis and lipid metabolism were measured by real-time polymerase chain reaction (7900 Sequence Detection System, Applied Biosystems, Applied Biosystems Italia, Monza, Italy) as referenced.<sup>21</sup> Briefly, 1 mg of total RNA was reverse-transcribed (RNA Reverse Transcription KIT, Applied Biosystems) and amplified using primers (300 nM) and probes (50 nM) selected using the Primer Express Software (Applied Biosystems). Primers for PGC-1 $\alpha$

amplification were as follows: forward: AGCAAGCTCTGATGCT CTGAAGGA; reverse: ACCGAAGTGAGGTGCTTATGCAGT. The probe sequence for PGC-1 $\alpha$  detection was TTCCAGAAGTC AGCGGCCTTGTCATAA. Primers for PPAR $\gamma$  amplification were as follows: forward: ACCAGGGAGTTCCTCAAAGC; reverse: GCAAACCTCAAACCTTAGGCTCCATAA. The probe sequence for PPAR $\gamma$  detection was TGCGGAAGCCCTTTGGTGA. The reference gene used was 28S rRNA.<sup>19,21</sup> Target and housekeeping genes were amplified separately, and their final quantitation was achieved using a relative standard curve. Results for each gene were divided by the corresponding 28S rRNA abundance and expressed as arbitrary units.

#### Nuclear factor- $\kappa$ B nuclear content, AKT insulin signalling, and plasma biochemical profile

Nuclear protein extracts for measurement of nuclear NF $\kappa$ B were obtained as previously reported.<sup>32</sup> Protein concentration in all samples was measured by spectrophotometer (BCA Protein Assay Reagent, Pierce, Rockford, IL, USA). For measurement of tissue p65 NF $\kappa$ B subunit a commercially available kit was used following manufacturer instructions (TransAM, Active Motif North America, Carlsbad, CA, USA). Total (T) and phosphorylated (P: activated) AKT muscle protein contents were determined using western blotting as previously described.<sup>20</sup> The P/T ratio was calculated as a marker of tissue AKT activation, and results were expressed as a percentage of sham value. Plasma insulin concentration was measured by enzyme-linked immunosorbent assay (Ultrasensitive ELISA; DRG, Springfield, NJ). Plasma glucose and triglycerides levels were determined by standard enzymatic colorimetric assays.<sup>21</sup>

#### C2C12 myotube experiments

C2C12 myoblasts were differentiated in myotubes as previously reported.<sup>33,34</sup> After 4 day incubation periods with differentiation medium and 18 h starvation, they were treated with AG (0.1 or 1  $\mu$ mol/L) for 48 h, followed by collection and processing. Adenosine triphosphate (ATP) production from cell preparations was measured by luciferin-luciferase luminometric assay,<sup>33–35</sup> and cytochrome c oxidase and citrate synthase activities were measured spectrophotometrically as referenced.<sup>19</sup>

#### Statistical analysis

All values are expressed as mean  $\pm$  SEM. Comparison of parameters among the three groups were performed using one-way analysis of variance followed by the Tukey post-hoc test. *P* values  $<0.05$  were considered statistically significant. Weight changes within each group were compared using paired *t*-test.

## Results

### Body weight, food intake, and plasma metabolic profile

No statistically significant differences in body weight among groups were observed at any time, and body weight was comparable at time of surgery in all groups despite a less pronounced body weight gain in the last ghrelin infusion period (Table 1). A general overall decline in food intake was observed for all groups between the first and the second ghrelin infusion period, but cumulative food intake remained comparable among the three groups during the whole infusion periods (Table 2). Plasma insulin, glucose, and triglycerides concentrations were comparable in all study groups (Table 3).

### Skeletal muscle mitochondrial enzyme activities and mitochondrial biogenesis transcript levels (Figure 1)

Myocardial infarction with placebo had lower skeletal muscle activities of both cytochrome c oxidase and citrate synthase (*P*  $< 0.05$  vs control; Figure 1). This alteration was associated with lower transcript levels of master regulators of mitochondrial biogenesis and lipid oxidation PGC-1 $\alpha$  and PPAR- $\gamma$  (Figure 2). Ghrelin treatment was in turn associated with higher activities of both enzymes compared with IMA-P

**Table 1** Body weights

	Time	Sham <i>n</i> = 14	IMA-P <i>n</i> = 18	IMA-AG <i>n</i> = 18
Body weight at surgery (g)	T0	227.9 $\pm$ 2.5	225.0 $\pm$ 2.1	227.4 $\pm$ 1.6
Body weight at start of treatment (g)	T28	322.5 $\pm$ 7.4	311.4 $\pm$ 5.8	316.1 $\pm$ 3.7
Final body weight (g)	T56	357.8 $\pm$ 7.8	339.4 $\pm$ 7.5	352.2 $\pm$ 5.4

Effects of continuous subcutaneous administration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on body weight. No statistical significant differences were observed among groups. Mean  $\pm$  SEM, *n* = 14–18/group. IMA-AG, myocardial infarction with gastric hormone acylated ghrelin; IMA-P, myocardial infarction with placebo

**Table 2** Food intake

	Time	Sham <i>n</i> = 14	IMA-P <i>n</i> = 18	IMA-AG <i>n</i> = 18
Average food intake (g/100 g/day)	T28-T56	5.43 $\pm$ 0.07	5.32 $\pm$ 0.065	5.48 $\pm$ 0.5

Effects of continuous subcutaneous administration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on average daily food intake during treatment. No statistical significant differences were observed among groups. Mean  $\pm$  SEM, *n* = 14–18/group. IMA-AG, myocardial infarction with gastric hormone acylated ghrelin; IMA-P, myocardial infarction with placebo

**Table 3** Animal characteristics

	Time	Sham <i>n</i> = 14	IMA-P <i>n</i> = 18	IMA-AG <i>n</i> = 18
Plasma glucose (mg/dL)	T56	112 ± 5	107 ± 9	121 ± 6
Plasma insulin (μU/mL)	T56	12.3 ± 2.1	12.8 ± 0.9	11.7 ± 1.3
Plasma triglycerides (mg/dL)	T56	0.73 ± 0.08	0.61 ± 0.04	0.72 ± 0.06

Effects of continuous subcutaneous administration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on final glucose, insulin, and triglyceride plasma levels. No statistical significant differences were observed among groups. Mean ± SEM, *n* = 14–18/group. IMA-AG, myocardial infarction with gastric hormone acylated ghrelin; IMA-P, myocardial infarction with placebo

(*P* < 0.05 vs IMA-P, *P* = NS vs control; Figure 1). Transcript levels of PGC-1α were also higher after AG treatment than in IMA-P animals (*P* < 0.05 vs IMA-P, *P* = NS vs control) whereas no effects of AG were observed on PPARγ expression (Figure 2).

Skeletal muscle nuclear factor-κB nuclear content and AKT phosphorylation (Figure 2)

Higher skeletal muscle nuclear NFκB content and lower AKT phosphorylation were observed in IMA-P rats compared with control animals. Ghrelin treatment was in turn associated with normalized nuclear NFκB and AKT phosphorylation (both *P* < 0.05 for IMA-AG vs IMA-P; *P* = NS for IMA-AG vs control).


Gastric hormone acylated ghrelin activities *in vitro* in C2C12 myotubes (Figure 3)

In order to determine potential direct effects of AG in skeletal muscle tissue, we further investigated its mitochondrial activities *in vitro* in C2C12 myotubes. Consistent with direct mitochondrial effects in skeletal muscle tissue, AG incubation resulted in enhanced mitochondrial ATP production as well as cytochrome c oxidase and citrate synthase activities (*P* < 0.05).


Liver mitochondrial enzyme activities and mitochondrial biogenesis transcript levels (Figure 4)

At variance with gastrocnemius muscle, liver activities of both cytochrome c oxidase and citrate synthase were not affected

**Figure 1** Skeletal muscle mitochondrial enzyme activities and mitochondrial biogenesis transcript levels. Effects of continuous subcutaneous administration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on citrate synthase (A) and cytochrome c oxidase (B) activity and on PGC1α (C) and PPARγ (D) gene expression in skeletal muscle. a.u., arbitrary units, \**P* < 0.05 versus other groups, mean ± SEM, *n* = 14–18/group. IMA-P, myocardial infarction with placebo; IMA-AG, myocardial infarction with gastric hormone acylated ghrelin.



**Figure 2** Skeletal muscle nuclear factor- $\kappa$ B (NF $\kappa$ B) nuclear content and AKT phosphorylation. Effects of continuous subcutaneous administration of AG (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on nuclear NF- $\kappa$ B (A), tissue triglycerides (B), and pAKT (C) levels in skeletal muscle. \* $P < 0.05$  vs. other groups, mean  $\pm$  SEM,  $n = 14$ – $18$ /group. IMA-P, myocardial infarction with placebo; IMA-AG, myocardial infarction with gastric hormone acylated ghrelin.




by IMA or AG treatment and were comparable in the three study groups. Transcript levels of master regulators of mitochondrial biogenesis and lipid oxidation were similarly comparable in control, IMA-P, and IMA-AG animals. Further supporting tissue-specific CHF and AG activities, no changes were observed in any groups also for NF $\kappa$ B nuclear translocation and AKT phosphorylation.

## Discussion

The current study demonstrated that (a) sustained peripheral acylated ghrelin treatment in a rodent model of IMA-induced chronic heart failure completely normalized a cluster of skeletal muscle mitochondrial dysfunction and tissue pro-inflammatory and insulin-desensitizing changes; (b) acylated ghrelin appears to act at least in part directly at skeletal muscle level because its mitochondrial effects are fully reproduced *in vitro* in muscle cells; (c) effects of chronic heart failure *per se* as well as those of acylated ghrelin treatment on energy metabolism, inflammation, and insulin signalling are tissue-specific and do not occur at hepatic level.

Mitochondrial dysfunction, inflammation, and insulin resistance have emerged in recent years as potentially causally related abnormalities with strong negative impact on skeletal muscle metabolism and function in chronic heart failure.<sup>3,10–15,17</sup> Comprehensive normalization of CHF-induced alterations therefore indicates acylated ghrelin as a novel potential treatment for skeletal muscle dysfunction and its negative prognostic impact in CHF patients.<sup>4,6,7</sup> The current findings are notably in excellent agreement with previous reports of mitochondrial effects of acylated ghrelin with enhanced skeletal muscle oxidative enzyme activities in healthy rodents<sup>19</sup> and normalized enzyme activities in experimental chronic kidney disease.<sup>21</sup> Anti-inflammatory and insulin-sensitizing AG activities were conversely also reported in healthy and obese rodent models<sup>20,27,36</sup> and *in vitro* in response to pharmacological induction of muscle cell damage.<sup>25</sup> Causal links and vicious cycles likely contribute to associations between muscle mitochondrial dysfunction, inflammation, and low insulin signalling in CHF. In particular, systemic pro-inflammatory changes are reported to occur in CHF, and they could lead to both mitochondrial and insulin signalling abnormalities in skeletal muscle.<sup>13,14</sup> Mitochondrial dysfunction is, however, in turn also a potential primary cause of tissue

**Figure 3** Gastric hormone acylated ghrelin (AG) activities *in vitro* in C2C12 myotubes. Effects of the incubation with increasing concentrations of AG or unacylated ghrelin versus control (Ct) on citrate synthase (A) and cytochrome c oxidase (B) activity and adenosine triphosphate (ATP) synthesis rate (C) in C2C12 myotubes. PPKM, pyruvate + palmitoyl-L-carnitine +  $\alpha$ -ketoglutarate + malate; PCM, palmitoyl-L-carnitine + malate; GM, glutamate + malate; SR, succinate + rotenone. \* $P < 0.05$  versus Ctrl,  $^{\$}P < 0.05$  versus AG 0.1  $\mu$ M, mean  $\pm$  SEM,  $n = 14$ –18/group.



inflammation and insulin resistance through enhanced reactive oxygen species generation by damaged organelles.<sup>17,18,34</sup>


A primary role of improved mitochondrial function in global tissue AG activities in the current model is strongly supported by AG-induced *in vitro* enhancement of mitochondrial ATP production and oxidative capacity of both Krebs cycle and respiratory chain enzymes. In the current study, we notably also observed a CHF-induced transcriptional suppression of master mitochondrial biogenesis and oxidative metabolism regulators; PGC1- $\alpha$  but not PPAR $\gamma$  expression was selectively normalized by AG treatment, and this finding is in agreement with a direct involvement of mitochondrial biogenesis in the observed stimulation of mitochondrial parameters. Further studies should directly confirm this hypothesis.

In the current study, we investigated acylated ghrelin effects in the established IMA-induced CHF model, and all studied animals showed evidence of impaired left-ventricular function. Under the current conditions, all groups had comparable body weight and food intake at different experimental stages. Consistent with CHF-induced catabolism, P-treated animals, however, had less pronounced growth and total weight gain during the second part of the acylated ghrelin infusion treatment (Day 42–56 from surgery; not shown) despite comparable food intake. Less pronounced growth

was conversely not observed in AG-treated animals, consistent with potential muscle mass preservation through the observed muscle anti-catabolic effects. Skeletal muscle weight was not available in the current study, and further experiments should directly aim at dissecting potential differential contributions of lean and fat tissues in acylated ghrelin anabolic activities.

Assessment of potential tissue-specificity of CHF-induced metabolic alterations as well as differential acylated ghrelin effects in different tissues was an additional aim of the current study. At variance with skeletal muscle, CHF had no relevant impact on hepatic mitochondrial, inflammatory, and insulin signalling parameters. This finding is consistent with available reports of clinically relevant hepatic abnormalities following acute heart failure and hemodynamic changes<sup>37</sup> while chronic alterations in heart function may only result in liver metabolic alterations at late disease stages. Lack of AG activities in liver tissue is also consistent with tissue-specific metabolic effects of AG on skeletal muscle and liver,<sup>19,20</sup> with potentially negative effects on hepatic insulin signalling and stimulation of hepatic glucogenic pathways in healthy lean rodents.<sup>19,20</sup> Under the current experimental conditions, lack of changes in hepatic metabolic parameters was also associated with no negative impact of AG on plasma glucose,

**Figure 4** Liver mitochondrial enzyme activities and mitochondrial biogenesis transcript levels. Effects of continuous subcutaneous administration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on citrate synthase activity (A), on PGC1 $\alpha$  (B), and PPAR $\gamma$  (C) gene expression and on tissue triglycerides (D) and pAKT (E) levels in the liver. Mean  $\pm$  SEM,  $n = 14$ – $18$ /group. IMA-P, myocardial infarction with placebo; IMA-AG, myocardial infarction with gastric hormone acylated ghrelin.



insulin, and triglycerides. These findings are in agreement with lack of effects in chronic kidney disease models,<sup>21</sup> thereby collectively supporting the concept that AG administration under various chronic disease conditions is metabolically safe and does not alter plasma biochemical profile as well as pivotal liver metabolic pathways.

In conclusion, we demonstrated that sustained peripheral AG treatment normalizes a CHF-induced cluster of skeletal muscle mitochondrial dysfunction, pro-inflammatory changes, and reduced insulin signalling. Acylated ghrelin activities at skeletal muscle level appear to be at least partly direct and independent because mitochondrial effects are fully reproduced *in vitro* in muscle cells. The metabolic impact of chronic heart failure *per se* and acylated ghrelin treatment are tissue-specific and do not occur at hepatic level. These findings collectively indicate AG as a potential novel treatment for CHF-associated muscle catabolic abnormalities, with potential positive impact on skeletal muscle function and patient outcome.

## Acknowledgements

The authors would like to thank Antonella Falcione and Francesca Bortolotti (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy) for excellent assistance *in vitro* studies. Clara Ferreira and Alessia Pirulli (Department of Medical Sciences, University of Trieste) are also acknowledged for excellent assistance in sample preparation and handling.

The authors certify that they comply with the ethical guidelines for authorship and publishing of the *Journal of Cachexia, Sarcopenia and Muscle*.<sup>38</sup>

## Conflict of interest

None declared.

## References

- McMurray JJ, Pfeffer MA. Heart failure. *Lancet* 2005;**365**:1877–1889.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task

- Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
3. Adams V, Reich B, Uhlemann M, Niebauer J. Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. *Am J Physiol Heart Circ Physiol* 2017;**313**:H72–H88.
  4. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. *Lancet* 1997;**349**:1050–1053.
  5. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. *J Am Coll Cardiol* 1997;**30**:1758–1764.
  6. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. *Nat Rev Cardiol* 2017;**14**:323–341.
  7. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. *Pharmacol Ther* 2009;**121**:227–252.
  8. Ebner N, Sliziuk V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. *ESC Heart Fail* 2015;**2**:58–68.
  9. Konishi M, Ishida J, von Haehling S, Anker SD, Springer J. Nutrition in cachexia: from bench to bedside. *J Cachexia Sarcopenia Muscle* 2016;**7**:107–109.
  10. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. *J Cachexia Sarcopenia Muscle* 2016;**7**:246–260.
  11. Murray AJ, Edwards LM, Clarke K. Mitochondria and heart failure. *Curr Opin Clin Nutr Metab Care* 2007;**10**:704–711.
  12. Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. *Heart Fail Rev* 2013;**18**:607–622.
  13. Jahng JW, Song E, Sweeney G. Crosstalk between the heart and peripheral organs in heart failure. *Exp Mol Med* 2016;**48**:e217.
  14. Remels AH, Gosker HR, Bakker J, Guttridge DC, Schols AM, Langen RC. Regulation of skeletal muscle oxidative phenotype by classical NF- $\kappa$ B signalling. *Biochim Biophys Acta* 2013;**1832**:1313–1325.
  15. Kempainen J, Tsuchida H, Stolen K, Karlsson H, Bjornholm M, Heinonen OJ, et al. Insulin signalling and resistance in patients with chronic heart failure. *J Physiol* 2003;**550**:305–315.
  16. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. *Diabetes* 2006;**55**:S9–S15.
  17. Ohta Y, Kinugawa S, Matsushima S, Ono T, Sobirin MA, Inoue N, et al. Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. *Am J Physiol Heart Circ Physiol* 2011;**300**:H1637–H1644.
  18. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. *J Clin Invest* 2008;**118**:2992–3002.
  19. Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. *Am J Physiol Endocrinol Metab* 2005;**288**:E228–E235.
  20. Barazzoni R, Zanetti M, Cattin MR, Visintin L, Vinci P, Cattin L, et al. Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats. *Obesity* 2007;**15**:2614–2623.
  21. Barazzoni R, Zhu X, Deboer M, Datta R, Culler MD, Zanetti M, et al. Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. *Kidney Int* 2010;**77**:23–28.
  22. Anker SD, Coats AJ, Morley JE. Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin. *J Cachexia Sarcopenia Muscle* 2015;**6**:275–277.
  23. Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. *J Clin Endocrinol Metab* 2004;**89**:5035–5042.
  24. Trippel TD, Holzendorf V, Halle M, Gelbrich G, Nolte K, Duvinage A, et al. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. *ESC Heart Fail* 2017;**4**:56–65.
  25. Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. *J Cachexia Sarcopenia Muscle* 2015;**6**:132–143.
  26. Hatanaka M, Konishi M, Ishida J, Saito M, Springer J. Novel mechanism of ghrelin therapy for cachexia. *J Cachexia Sarcopenia Muscle* 2015;**6**:393.
  27. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. *Endocrinology* 2008;**149**:827–835.
  28. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. *Endocrinology* 2007;**148**:3004–3012.
  29. Palus S, Schur R, Akashi YJ, Bockmeyer B, Datta R, Halem H, et al. Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. *PLoS One* 2011;**6**:e26865.
  30. Lenk K, Palus S, Schur R, Datta R, Dong J, Culler MD, et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. *J Cachexia Sarcopenia Muscle* 2013;**4**:63–69.
  31. Barazzoni R, Zanetti M, Bosutti A, Biolo G, Vitali-Serdoz L, Stebel M, et al. Moderate caloric restriction, but not physiological hyperleptinemia per se, enhances mitochondrial oxidative capacity in rat liver and skeletal muscle—tissue-specific impact on tissue triglyceride content and AKT activation. *Endocrinology* 2005;**146**:2098–2106.
  32. Barazzoni R, Zanetti M, Semolic A, Cattin MR, Pirulli A, Cattin L, et al. High-fat diet with acyl-ghrelin treatment leads to weight gain with low inflammation, high oxidative capacity and normal triglycerides in rat muscle. *PLoS One* 2011;**6**:e26224.
  33. Gortan Cappellari G, Semolic A, Ruozzi G, Vinci P, Guarnieri G, Bortolotti F, et al. Unacylated ghrelin normalizes skeletal muscle oxidative stress and prevents muscle catabolism by enhancing tissue mitophagy in experimental chronic kidney disease. *FASEB J: Official Publication of the Federation of American Societies for Experimental Biology* 2017; <https://doi.org/10.1096/fj.201700126R>.
  34. Gortan Cappellari G, Zanetti M, Semolic A, Vinci P, Ruozzi G, Falcione A, et al. Unacylated ghrelin reduces skeletal muscle reactive oxygen species generation and inflammation and prevents high-fat diet-induced hyperglycemia and whole-body insulin resistance in rodents. *Diabetes* 2016;**65**:874–886.
  35. Barazzoni R, Zanetti M, Gortan Cappellari G, Semolic A, Boschelle M, Codarin E, et al. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor- $\kappa$ B inhibitor (I $\kappa$ B)-nuclear factor- $\kappa$ B (NF $\kappa$ B) activation in rat muscle, in the absence of mitochondrial dysfunction. *Diabetologia* 2012;**55**:773–782.
  36. Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. *J Clin Invest* 2013;**123**:611–622.
  37. Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2017;**19**:821–836.
  38. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. *J Cachexia Sarcopenia Muscle* 2015;**6**:315–316.